Patented technology applied in SynGEM, a needle-free nasal spray vaccine against respiratory syncytial virus * Re-Issuance of U.S. Patent No. RE 47,471 further bolsters Mucosis’ intellectual property portfolio Groningen / Odijk, The Netherlands, July 2, 2019 – The trustee of biotech company Mucosis B.V., Mr. Holtz LLM and Virtuvax B.V. today announce that the US Patent Office (USPTO) has issued patent RE. 47,471 dated July 2, 2019. The patent is a reissue of Mucosis’ US Pat